Voglibose Repaglinide Tablet
Description
REPAROOT V 1/0.5
Voglibose 0.5 mg and Repaglinide 1 mg Tablets
Division: DIABGLYM
Composition
Each tablet contains:
Voglibose IP — 0.5 mg
Repaglinide IP — 1 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Oral tablet
Product Description
REPAROOT V 1/0.5 is a scientifically balanced oral antidiabetic combination containing Voglibose 0.5 mg and Repaglinide 1 mg, formulated for the effective management of Type 2 Diabetes Mellitus, particularly in patients with significant postprandial hyperglycemia. This combination provides dual glycemic control by reducing post-meal glucose absorption and enhancing meal-time insulin secretion.
Repaglinide is a rapid-acting insulin secretagogue that stimulates pancreatic beta cells to release insulin in response to meals, while Voglibose is an alpha-glucosidase inhibitor that delays the digestion and absorption of carbohydrates in the intestine. Together, they effectively control postprandial blood glucose excursions and improve overall glycemic control.
REPAROOT V 1/0.5 is particularly beneficial for patients with Type 2 diabetes who have elevated postprandial glucose levels, inadequate glycemic control with monotherapy, early diabetes requiring combination therapy, metabolic syndrome, obesity-associated diabetes, and individuals requiring intensive meal-time glucose control.
Technical Knowledge of Voglibose and Repaglinide
Voglibose inhibits intestinal alpha-glucosidase enzymes located in the brush border of the small intestine, delaying the breakdown of complex carbohydrates into absorbable monosaccharides. This results in slower glucose absorption and reduced postprandial hyperglycemia.
Repaglinide belongs to the meglitinide class of oral antidiabetic agents and stimulates insulin secretion by closing ATP-sensitive potassium channels in pancreatic beta cells. This causes membrane depolarization, calcium influx, and rapid glucose-dependent insulin release.
The combination provides complementary mechanisms that target both carbohydrate absorption and insulin secretion, resulting in superior postprandial glucose control.
Mechanism of Action
Voglibose delays intestinal carbohydrate digestion and glucose absorption, reduces postprandial glucose spikes, and lowers glycemic variability.
Repaglinide stimulates pancreatic beta cells, promotes rapid insulin secretion, reduces postprandial glucose excursions, and improves overall glycemic control.
Key Benefits
Excellent control of postprandial blood glucose
Dual mechanism for meal-time glucose management
Rapid insulin secretory response
Delayed carbohydrate absorption
Improves overall glycemic control
Reduces glucose fluctuations after meals
Supports comprehensive diabetes management
Suitable for long-term diabetes therapy under medical supervision
Clinical Applications
REPAROOT V 1/0.5 is commonly prescribed for Type 2 Diabetes Mellitus, postprandial hyperglycemia, inadequate glycemic control with single-drug therapy, combination oral antidiabetic therapy, metabolic syndrome-associated diabetes, obesity-related diabetes, and patients requiring intensive post-meal glucose control.
Facts About Voglibose and Repaglinide
Voglibose is particularly effective in controlling postprandial hyperglycemia by slowing intestinal carbohydrate absorption, while Repaglinide provides rapid meal-time insulin secretion. This combination addresses two major contributors to postprandial glucose elevation and is widely used in Asian populations where carbohydrate-rich diets contribute significantly to postprandial hyperglycemia.
Key Facts
Dual oral antidiabetic combination therapy
Voglibose 0.5 mg for postprandial carbohydrate control
Repaglinide 1 mg for rapid meal-time insulin secretion
Excellent postprandial glucose management
Supports comprehensive glycemic control
Evidence-based diabetes combination therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
REPAROOT V 1/0.5 is an excellent product for PCD Pharma Franchise, Diabetology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of Type 2 diabetes, obesity, metabolic syndrome, and postprandial hyperglycemia creates strong prescription demand and long-term market potential for this combination.
Why Choose REPAROOT V 1/0.5 for PCD Pharma Franchise?
High prescription potential
Strong physician and diabetologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Voglibose 0.5 mg and Repaglinide 1 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented formulation
Moisture-controlled tablet manufacturing
Blister and Alu-Alu packaging options
REPAROOT V 1/0.5 from DIABGLYM combines effective postprandial glucose control, dual-mechanism diabetes management, evidence-based antidiabetic therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, diabetologists, endocrinologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Voglibose and Repaglinide combination.
